Efficacy and prognostic factors of Xindilizumab combined with XELIRI regimen in the treatment of colorectal cancer
Objective To explore the efficacy of Xindilizumab combined with XELIRI regimen in the treatment of colorectal cancer and analyze prognostic factors.Methods From January 2019 to December 2020,a total of 82 patients with colorectal cancer were selected and divided into the control group(41 cases,treated with XELIRI regimen)and the study group(41 cases,treated with Xindilizumab combined with XELIRI regimen)by treatment.The therapeutic efficacy and adverse drug reactions of the two groups were compared.The patients were followed up for 3 year to analyze the influencing factors of poor prognosis.Results Compared with the control group,the study group had higher ORR(22％vs 20％)and DCR(73％vs 63％),but the difference was not statisti-cally significant(P＞0.05).Compared with the control group,the incidences of nausea,vomiting,di-arrhea,fatigue,elevated transaminases,decreased hemoglobin,thrombocytopenia,and decreased neutropenia in the study group were not statistically significant(P＞0.05),while the incidence of rash,proteinuria,and hypothy-roidism was higher in the study group(P＜0.05).After a 3-year follow-up,there were 9 cases of poor prognosis in the study group and 22 cases in the control group(P＜0.05).Univariate analysis showed that compared with the good prognosis group,the KPS score＜70,lymph node metastasis,and treatment methods in the poor prognosis group were statistically significance(P＜0.05),while the other factors were not statistically significance(P＞0.05).According to Cox analysis of survival function,KPS score ≥ 70 was a protective factor for poor prognosis(P＜0.05),while lymph node metas-tasis and XELIRI regimen were risk factors for poor prognosis(P＜0.05).Conclusion There is potential benefits from the combination of Xindilizumab and XELIRI regimen in the treatment of colorectal cancer,with overall tol-erable drug adverse reactions and controllable safety.The prognosis of colorectal cancer patients is related to KPS score,lymph node metastasis,and treatment methods.
万方数据
维普
